Oct 29 (Reuters) - German healthcare group Fresenius FREG.DE beat third-quarter revenue forecasts on Tuesday as softer revenue growth in North America was offset by growth of its infusions drugs unit Kabi in emerging markets.
The group confirmed its full-year guidance after third-quarter revenues rose by 8% to 8.9 billion euros in the third quarter, compared to 8.7 billion euros in a company-compiled consensus.
(Reporting by Zuzanna Szymanska in Gdansk Editing by Tomasz Janowski)
((email@example.com; + 48 58 778 52 86;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.